Goldman Sachs Group Inc Arcus Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 648,074 shares of RCUS stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

648,074

Previous 914,208 29.11%

Holding current value

$10.8 Million

Previous $7.18 Million 26.49%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.87 - $10.03 $1.83 Million - $2.67 Million	-266,134 Reduced 29.11%	648,074 $5.28 Million
Q1 2025 May 09, 2025	BUY	$7.85 - $15.24 $3.7 Million - $7.17 Million	470,755 Added 106.16%	914,208 $7.18 Million
Q4 2024 Feb 11, 2025	SELL	$14.28 - $18.44 $3.71 Million - $4.79 Million	-259,883 Reduced 36.95%	443,453 $6.6 Million
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $911,233 - $1.2 Million	66,562 Added 10.45%	703,336 $10.8 Million
Q2 2024 Aug 13, 2024	BUY	$14.59 - $18.48 $5.64 Million - $7.14 Million	386,461 Added 154.39%	636,774 $9.7 Million
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $5.07 Million - $6.9 Million	-341,978 Reduced 57.74%	250,313 $4.73 Million
Q4 2023 Feb 13, 2024	BUY	$13.43 - $19.63 $54,834 - $80,149	4,083 Added 0.69%	592,291 $11.3 Million
Q3 2023 May 14, 2024	SELL	$17.62 - $23.54 $71,942 - $96,113	-4,083 Reduced 0.69%	588,208 $10.6 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $174,913 - $233,681	-9,927 Reduced 1.66%	588,208 $10.6 Million
Q2 2023 May 14, 2024	SELL	$16.97 - $22.03 $3.5 Million - $4.55 Million	-206,399 Reduced 25.65%	598,135 $12.1 Million
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $3.5 Million - $4.55 Million	-206,399 Reduced 25.65%	598,135 $12.1 Million
Q1 2023 May 14, 2024	BUY	$15.96 - $23.15 $672,139 - $974,939	42,114 Added 5.52%	804,534 $14.7 Million
Q1 2023 May 11, 2023	BUY	$15.96 - $23.15 $672,139 - $974,939	42,114 Added 5.52%	804,534 $14.7 Million
Q4 2022 May 14, 2024	SELL	$19.7 - $35.71 $1.99 Million - $3.61 Million	-100,965 Reduced 11.69%	762,420 $15.8 Million
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $1.99 Million - $3.61 Million	-100,965 Reduced 11.69%	762,420 $15.8 Million
Q3 2022 May 14, 2024	SELL	$23.23 - $30.07 $2.57 Million - $3.33 Million	-110,747 Reduced 11.37%	863,385 $22.6 Million
Q3 2022 Nov 10, 2022	SELL	$23.23 - $30.07 $2.57 Million - $3.33 Million	-110,747 Reduced 11.37%	863,385 $22.6 Million
Q2 2022 May 14, 2024	BUY	$17.23 - $37.73 $6.58 Million - $14.4 Million	381,841 Added 64.47%	974,132 $24.7 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $12.5 Million - $27.5 Million	727,692 Added 295.28%	974,132 $24.7 Million
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $3.87 Million - $5.6 Million	133,979 Added 119.13%	246,440 $7.78 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $1.68 Million - $2.6 Million	53,609 Added 91.09%	112,461 $4.55 Million
Q3 2021 Nov 10, 2021	BUY	$26.93 - $37.68 $1.58 Million - $2.22 Million	58,852 New	58,852 $2.05 Million

Others Institutions Holding RCUS

# of Institutions

209

Shares Held

67M

Call Options Held

3.18M

Put Options Held

167K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.2B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Arcus Biosciences, Inc. Transaction History